Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study
RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. Also, monoclonal antibodies, such as gemtuzumab ozogamicin, can find cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
PURPOSE: This phase II trial is studying how well gemtuzumab ozogamicin works in treating young patients who are undergoing remission induction, intensification therapy, and allogeneic bone marrow transplant for newly diagnosed acute myeloid leukemia.
調査の概要
状態
条件
詳細な説明
OBJECTIVES:
Primary
- Determine the safety of gemtuzumab ozogamicin in children with newly diagnosed acute myeloid leukemia undergoing intensive remission induction and intensification therapy.
- Determine the complete remission rate of patients treated with this regimen.
Secondary
- Determine the feasibility of performing biological studies (e.g., FLT3-ITD and MRD) for risk group stratification in these patients.
- Determine the effect of karyotypic abnormalities on survival in patients treated with this regimen.
OUTLINE: This is a multicenter study.
- Induction I: Patients receive high-dose cytarabine (ARA-C) IV twice daily on days 1-10; daunorubicin IV over 6 hours on days 1, 3, and 5; etoposide IV over 4 hours on days 1-5; and gemtuzumab ozogamicin IV over 2 hours on day 6. Patients with CNS-negative disease receive ARA-C intrathecally (IT) on day 1. Patients with CNS-positive disease receive ARA-C IT twice weekly for 2-3 weeks. Between days 28-35, patients are evaluated. Patients achieving remission or who have no more than 20% blasts proceed to induction II.
- Induction II: Patients receive ARA-C IV twice daily on days 1-8; ARA-C IT on day 1; and daunorubicin IV and etoposide IV as in induction I. Between days 28-35 patients are evaluated. Patients achieving complete remission proceed to intensification course I.
- Intensification course I: Patients receive ARA-C IV over 1 hour twice daily on days 1-5; ARA-C IT as in induction II; and etoposide IV over 1 hour on days 1-5. Patients are evaluated at day 28. Patients with a 5/6 or 6/6 matched family donor proceed to allogeneic bone marrow transplantation. All other patients in complete remission proceed to intensification course II.
- Intensification course II: Patients receive ARA-C IV over 2 hours twice daily on days 1-4; ARA-C IT as in induction II; mitoxantrone IV over 1 hour on days 3-6; and gemtuzumab ozogamicin IV over 2 hours on day 7. Patients are evaluated on day 28 and then proceed to intensification course III.
- Intensification course III: Patients receive ARA-C IV over 3 hours twice daily on days 1, 2, 8, and 9 and asparaginase intramuscularly on days 2 and 9.
- Allogeneic bone marrow transplantation: Patients receive a preparative regimen comprising busulfan IV over 2 hours 4 times daily on days -9 to -6 and cyclophosphamide IV over 1 hour once daily on days -5 to -2. Allogeneic stem cells are infused on day 0.
- Graft-versus-host disease prophylaxis: Patients receive oral or IV cyclosporine twice daily on days -1 to 50 and methotrexate IV once daily on days 1, 3, 6, and 11.
In all courses, treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed monthly for 6 months, every 2 months for 6 months, every 4 months for 1 year, every 6 months for 1 year, and then annually thereafter.
PROJECTED ACCRUAL: A total of 330 patients will be accrued for this study.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35294
- Comprehensive Cancer Center at University of Alabama at Birmingham
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85016-7710
- Phoenix Children's Hospital
-
-
Arkansas
-
Little Rock、Arkansas、アメリカ、72205
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
-
-
California
-
Downey、California、アメリカ、90242-2814
- Southern California Permanente Medical Group
-
Loma Linda、California、アメリカ、92354-2870
- Loma Linda University Cancer Institute at Loma Linda University Medical Center
-
Long Beach、California、アメリカ、90801
- Jonathan Jaques Children's Cancer Center at Miller Children's Hospital
-
Los Angeles、California、アメリカ、90027
- Children's Hospital Los Angeles
-
Los Angeles、California、アメリカ、90048-1865
- Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
-
Madera、California、アメリカ、93638-8762
- Children's Hospital Central California
-
Oakland、California、アメリカ、94609-1809
- Children's Hospital and Research Center - Oakland
-
Orange、California、アメリカ、92668
- Children's Hospital of Orange County
-
Sacramento、California、アメリカ、95817
- University of California Davis Cancer Center
-
Sacramento、California、アメリカ、95825
- Kaiser Permanente Medical Center - Oakland
-
Sacramento、California、アメリカ、95819
- Sutter Cancer Center
-
San Diego、California、アメリカ、92123-4282
- Children's Hospital and Health Center - San Diego
-
-
Colorado
-
Denver、Colorado、アメリカ、80218-1088
- Children's Hospital Cancer Center
-
-
Connecticut
-
Hartford、Connecticut、アメリカ、06106
- Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
-
-
Delaware
-
Wilmington、Delaware、アメリカ、19899
- Alfred I. DuPont Hospital for Children
-
-
District of Columbia
-
Washington、District of Columbia、アメリカ、20010-2970
- Children's National Medical Center
-
Washington、District of Columbia、アメリカ、20007-2197
- Lombardi Cancer Center at Georgetown University Medical Center
-
-
Florida
-
Ft. Lauderdale、Florida、アメリカ、33316
- Broward General Medical Center Cancer Center
-
Ft. Myers、Florida、アメリカ、33908
- Lee Cancer Care of Lee Memorial Health System
-
Gainesville、Florida、アメリカ、32610
- University of Florida Shands Cancer Center
-
Hollywood、Florida、アメリカ、33021
- Memorial Cancer Institute at Memorial Regional Hospital
-
Jacksonville、Florida、アメリカ、32207
- Nemours Children's Clinic
-
Miami、Florida、アメリカ、33155
- Miami Children's Hospital
-
Miami、Florida、アメリカ、33176
- Baptist-South Miami Regional Cancer Program
-
Miami、Florida、アメリカ、33101
- University of Miami Sylvester Comprehensive Cancer Center
-
Orlando、Florida、アメリカ、32806
- M.D. Anderson Cancer Center - Orlando
-
Orlando、Florida、アメリカ、32804
- Florida Hospital Cancer Institute at Florida Hospital Orlando
-
Pensacola、Florida、アメリカ、32504
- Sacred Heart Cancer Center at Sacred Heart Hospital
-
St. Petersburg、Florida、アメリカ、33701
- All Children's Hospital
-
Tampa、Florida、アメリカ、33607
- St. Joseph's Cancer Institute at St. Joseph's Hospital
-
West Palm Beach、Florida、アメリカ、33407
- Kaplan Cancer Center at St. Mary's Medical Center
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- Emory University Hospital - Atlanta
-
Savannah、Georgia、アメリカ、31404-6283
- Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu、Hawaii、アメリカ、95813
- Cancer Research Center of Hawaii
-
-
Idaho
-
Boise、Idaho、アメリカ、83712-6297
- St. Luke's Mountain States Tumor Institute - Boise
-
-
Illinois
-
Chicago、Illinois、アメリカ、60614
- Children's Memorial Hospital - Chicago
-
Chicago、Illinois、アメリカ、60637-1463
- University of Chicago Cancer Research Center
-
Park Ridge、Illinois、アメリカ、60068-1174
- Lutheran General Cancer Care Center
-
Springfield、Illinois、アメリカ、62794-9230
- Southern Illinois University School of Medicine
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46260
- St. Vincent Indianapolis Hospital
-
Indianapolis、Indiana、アメリカ、46202-5225
- Indiana University Cancer Center
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242-1083
- Holden Comprehensive Cancer Center at University of Iowa
-
-
Kansas
-
Wichita、Kansas、アメリカ、67214
- Wesley Medical Center
-
Wichita、Kansas、アメリカ、67214
- Via Christi Cancer Center at Via Christi Regional Medical Center
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40506
- Markey Cancer Center at University of Kentucky Chandler Medical Center
-
Louisville、Kentucky、アメリカ、40202-1822
- Kosair Children's Hospital
-
-
Maine
-
Bangor、Maine、アメリカ、04401
- CancerCare of Maine at Eastern Maine Medial Center
-
Scarborough、Maine、アメリカ、04074-9308
- Maine Children's Cancer Program
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21215
- Alvin and Lois Lapidus Cancer Institute at Sinai Hospital
-
Baltimore、Maryland、アメリカ、21287-5001
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02111
- Floating Hospital for Children
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109-0238
- C.S. Mott Children's Hospital at University of Michigan
-
Detroit、Michigan、アメリカ、48201
- Barbara Ann Karmanos Cancer Institute
-
East Lansing、Michigan、アメリカ、48824-1313
- Breslin Cancer Center at Ingham Regional Medical Center
-
Grand Rapids、Michigan、アメリカ、49503-2560
- Spectrum Health Cancer Care - Butterworth Campus
-
Grosse Point Woods、Michigan、アメリカ、48236
- Van Elslander Cancer Center at St. John Hospital and Medical Center
-
Kalamazoo、Michigan、アメリカ、49007-5341
- CCOP - Kalamazoo
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55404
- Children's Hospitals and Clinics - Minneapolis/St. Paul
-
Minneapolis、Minnesota、アメリカ、55455-0392
- Fairview University Medical Center - University Campus
-
Rochester、Minnesota、アメリカ、55905-0001
- Mayo Clinic Cancer Center
-
-
Mississippi
-
Jackson、Mississippi、アメリカ、39216-4505
- University of Mississippi Medical Center
-
Keesler AFB、Mississippi、アメリカ、39534-2511
- Keesler Medical Center - Keesler Air Force Base
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64108
- Children's Mercy Hospital
-
St. Louis、Missouri、アメリカ、63110
- Siteman Cancer Center at Barnes-Jewish Hospital
-
St. Louis、Missouri、アメリカ、63104
- Cardinal Glennon Children's Hospital
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68114-4113
- Children's Hospital of Omaha
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89109-2306
- Sunrise Hospital and Medical Center
-
-
New Jersey
-
Hackensack、New Jersey、アメリカ、07601
- Hackensack University Medical Center
-
Livingston、New Jersey、アメリカ、07039
- St. Barnabas Medical Center
-
New Brunswick、New Jersey、アメリカ、08901
- Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
-
Newark、New Jersey、アメリカ、07112-2094
- Newark Beth Israel Medical Center
-
Paterson、New Jersey、アメリカ、07503
- St. Joseph's Hospital and Medical Center
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87131-0001
- University of New Mexico Cancer Research and Treatment Center
-
-
New York
-
Bronx、New York、アメリカ、10467
- Albert Einstein Cancer Center at Albert Einstein College of Medicine
-
Brooklyn、New York、アメリカ、11219
- Maimonides Medical Center
-
Brooklyn、New York、アメリカ、11201-5493
- Brooklyn Hospital Center
-
Buffalo、New York、アメリカ、14263
- Roswell Park Cancer Institute
-
Mineola、New York、アメリカ、11501
- Winthrop University Hospital
-
New Hyde Park、New York、アメリカ、11040
- Schneider Children's Hospital
-
New York、New York、アメリカ、10032-1537
- Herbert Irving Comprehensive Cancer Center at Columbia University
-
Syracuse、New York、アメリカ、13210
- SUNY Upstate Medical University Hospital
-
Valhalla、New York、アメリカ、10595
- New York Medical College
-
-
North Carolina
-
Asheville、North Carolina、アメリカ、28801-4690
- Mission Hospitals - Memorial Campus
-
Chapel Hill、North Carolina、アメリカ、27599-7220
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
-
Charlotte、North Carolina、アメリカ、28233
- Presbyterian Cancer Center at Presbyterian Hospital
-
Charlotte、North Carolina、アメリカ、28232
- Blumenthal Cancer Center at Carolinas Medical Center
-
Greenville、North Carolina、アメリカ、27834
- Leo W. Jenkins Cancer Center at Pitt County Memorial Hospital
-
Winston-Salem、North Carolina、アメリカ、27157-1081
- Comprehensive Cancer Center at Wake Forest University
-
-
North Dakota
-
Fargo、North Dakota、アメリカ、58122
- CCOP - MeritCare Hospital
-
-
Ohio
-
Akron、Ohio、アメリカ、44308-1062
- Children's Hospital Medical Center of Akron
-
Cincinnati、Ohio、アメリカ、45229-3039
- Cincinnati Children's Hospital Medical Center
-
Cleveland、Ohio、アメリカ、44106-5000
- Rainbow Babies and Children's Hospital
-
Cleveland、Ohio、アメリカ、44195-5217
- Cleveland Clinic Taussig Cancer Center
-
Columbus、Ohio、アメリカ、43205-2696
- Columbus Children's Hospital
-
Dayton、Ohio、アメリカ、45404-1815
- Children's Medical Center - Dayton
-
Toledo、Ohio、アメリカ、43606
- Toledo Hospital
-
Toledo、Ohio、アメリカ、43608
- Medical College of Ohio Cancer Institute
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- Oklahoma University Medical Center
-
-
Oregon
-
Portland、Oregon、アメリカ、97201-3098
- Cancer Institute at Oregon Health and Science University
-
-
Pennsylvania
-
Danville、Pennsylvania、アメリカ、17822-1320
- Geisinger Medical Center
-
Hershey、Pennsylvania、アメリカ、17033-0850
- Penn State Cancer Institute at Milton S. Hershey Medical Center
-
Philadelphia、Pennsylvania、アメリカ、19104-9786
- Children's Hospital of Philadelphia
-
Philadelphia、Pennsylvania、アメリカ、19134
- St. Christopher's Hospital for Children
-
Pittsburgh、Pennsylvania、アメリカ、15213-2583
- Children's Hospital of Pittsburgh
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- Hollings Cancer Center at Medical University of South Carolina
-
Columbia、South Carolina、アメリカ、29203-6897
- Palmetto Health South Carolina Cancer Center
-
-
South Dakota
-
Sioux Falls、South Dakota、アメリカ、57117-5039
- Sioux Valley Hospital and University of South Dakota Medical Center
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37232-6310
- Vanderbilt-Ingram Cancer Center
-
-
Texas
-
Amarillo、Texas、アメリカ、79106
- Texas Tech University Health Sciences Center School of Medicine
-
Austin、Texas、アメリカ、78701
- Children's Hospital of Austin
-
Corpus Christi、Texas、アメリカ、78411-1721
- Driscoll Children's Hospital
-
Dallas、Texas、アメリカ、75390-9063
- Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
-
Lubbock、Texas、アメリカ、79410
- Covenant Children's Hospital
-
San Antonio、Texas、アメリカ、78229-3993
- Methodist Children's Hospital of South Texas
-
San Antonio、Texas、アメリカ、78207
- University of Texas Health Science Center at San Antonio
-
Temple、Texas、アメリカ、76508
- CCOP - Scott and White Hospital
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84113-1100
- Primary Children's Medical Center
-
-
Vermont
-
Burlington、Vermont、アメリカ、05405
- Fletcher Allen Health Care - University Health Center Campus
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- INOVA Fairfax Hospital
-
Richmond、Virginia、アメリカ、23298-0121
- Massey Cancer Center at Virginia Commonwealth University
-
Roanoke、Virginia、アメリカ、24029
- Carilion Cancer Center of Western Virginia
-
-
Washington
-
Seattle、Washington、アメリカ、98105
- Children's Hospital and Regional Medical Center - Seattle
-
Spokane、Washington、アメリカ、99220-2555
- Providence Cancer Center at Sacred Heart Medical Center
-
Tacoma、Washington、アメリカ、98431
- Madigan Army Medical Center
-
Tacoma、Washington、アメリカ、98405
- Mary Bridge Children's Hospital and Health Center - Tacoma
-
-
West Virginia
-
Charleston、West Virginia、アメリカ、25302
- West Virginia University - Robert C. Byrd Health Sciences Center - Charleston Division
-
Huntington、West Virginia、アメリカ、25701
- Cabell Huntington Hospital
-
-
Wisconsin
-
Green Bay、Wisconsin、アメリカ、54301
- St. Vincent Hospital
-
La Crosse、Wisconsin、アメリカ、54601-5429
- Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
-
Madison、Wisconsin、アメリカ、53792-0001
- University of Wisconsin Comprehensive Cancer Center
-
Milwaukee、Wisconsin、アメリカ、53226
- Midwest Children's Cancer Center
-
-
-
-
New South Wales
-
Westmead、New South Wales、オーストラリア、2145
- Westmead Hospital
-
-
Queensland
-
Herston, Brisbane、Queensland、オーストラリア、4029
- Office of S. David Lang
-
-
Western Australia
-
Perth、Western Australia、オーストラリア、6001
- Princess Margaret Hospital for Children
-
-
-
-
Alberta
-
Calgary、Alberta、カナダ、T2T 5C7
- Alberta Children's Hospital
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V6H 3V4
- Children's & Women's Hospital of British Columbia
-
-
Manitoba
-
Winnipeg、Manitoba、カナダ、R3E 0V9
- CancerCare Manitoba
-
-
Newfoundland and Labrador
-
St. John's、Newfoundland and Labrador、カナダ、A1B 3V6
- Janeway Children's Health and Rehabilitation Centre
-
-
Nova Scotia
-
Halifax、Nova Scotia、カナダ、B3K 6R8
- IWK Health Centre
-
-
Ontario
-
Hamilton、Ontario、カナダ、L8N 3Z5
- McMaster Children's Hospital at Hamilton Health Sciences
-
-
Quebec
-
Montreal、Quebec、カナダ、H3T 1C5
- Hôpital Sainte Justine
-
Montreal、Quebec、カナダ、H3H 1P3
- McGill Cancer Centre at McGill University
-
Ste-Foy、Quebec、カナダ、G1V 4G2
- Centre Hospitalier Universitaire de Quebec
-
-
-
-
Chihuahua
-
Bern、Chihuahua、スイス、3010
- Swiss Pediatric Oncology Group Bern
-
-
-
-
-
Santurce、プエルトリコ、00912
- San Jorge Children's Hospital
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
説明
DISEASE CHARACTERISTICS:
Newly diagnosed primary acute myeloid leukemia (AML)
- At least 20% bone marrow blasts
Meets the customary FAB criteria for AML
- Patients with cytopenias and bone marrow blasts who do not meet the FAB criteria are eligible provided they have a karyotypic abnormality characteristic of de novo AML (e.g., t[8;21], inv16, or t[16;16]) OR they have the unequivocal presence of megakaryoblasts
- Isolated granulocytic sarcoma (myeloblastoma) allowed regardless of the results outlined above
- Previously untreated disease
- No promyelocytic leukemia (FAB M3)
- No documented myelodysplastic syndromes (preleukemia) (e.g., chronic myelomonocytic leukemia, refractory anemia [RA], RA with excess blasts, or RA with ringed sideroblasts)
- No juvenile myelomonocytic leukemia
- No Fanconi's anemia, Kostmann syndrome, Shwachman syndrome, or any other known bone marrow failure syndrome
- No Down syndrome
PATIENT CHARACTERISTICS:
Age
- 1 month to 21 years* NOTE: *Children under 1 month of age who have progressive disease are allowed
Performance status
- Karnofsky 50-100% (over 16 years of age) OR
- Lansky 50-100% (ages 1 to 16)* NOTE: Children under 1 year of age do not require a performance status
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- No inadequate liver function
Renal
- No inadequate renal function
- No hyperuricemia (greater than 8.0 mg/dL)
- Creatinine clearance or radioisotope glomerular filtration rate (GFR) at least 70 mL/min OR an equivalent normal GFR OR
- Creatinine no greater than 1.5 times normal
Cardiovascular
- Shortening fraction at least 27% by echocardiogram OR
- Ejection fraction at least 50% by MUGA
Pulmonary
- No proven or suspected pneumonia
Other
- Not pregnant or nursing
- No proven or suspected sepsis or meningitis
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- No prior chemotherapy except intrathecal cytarabine administered that was administered at diagnosis
Endocrine therapy
- Prior topical and inhalation steroids allowed
- No concurrent steroids as antiemetics
Radiotherapy
- No prior radiotherapy
Surgery
- Not specified
Other
- No prior antileukemic therapy
- No concurrent pressor agent or ventilatory support unless approved by the study chair
- No concurrent participation in another COG therapeutic study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- マスキング:なし(オープンラベル)
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
|---|
|
安全性
|
|
完全寛解率
|
二次結果の測定
結果測定 |
|---|
|
実現可能性
|
|
Effect of karyotypic abnormalities
|
協力者と研究者
捜査官
- スタディチェア:Janet Franklin, MD, MPH、Children's Hospital Los Angeles
出版物と役立つリンク
一般刊行物
- Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Godwin JE, Reaman GH, Willman CL, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S. Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG. Blood. 2011 Oct 27;118(17):4561-6. doi: 10.1182/blood-2011-04-348888. Epub 2011 Aug 26.
- Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, Raimondi SC, Hirsch B, Franklin J, Walter RB, Gamis A, Meshinchi S. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood. 2012 Apr 19;119(16):3705-11. doi: 10.1182/blood-2011-12-398370. Epub 2012 Feb 29.
- Vujkovic M, Attiyeh EF, Ries RE, Goodman EK, Ding Y, Kavcic M, Alonzo TA, Wang YC, Gerbing RB, Sung L, Hirsch B, Raimondi S, Gamis AS, Meshinchi S, Aplenc R. Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report. Blood. 2017 Jun 8;129(23):3051-3058. doi: 10.1182/blood-2017-03-772384. Epub 2017 Apr 14.
- Ho PA, Kuhn J, Gerbing RB, Pollard JA, Zeng R, Miller KL, Heerema NA, Raimondi SC, Hirsch BA, Franklin JL, Lange B, Gamis AS, Alonzo TA, Meshinchi S. WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group. J Clin Oncol. 2011 Feb 20;29(6):704-11. doi: 10.1200/JCO.2010.31.9327. Epub 2010 Dec 28.
- Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, Gerbing RB, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Reaman GH, Baker LH, Willman CL, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia. 2010 May;24(5):909-13. doi: 10.1038/leu.2010.56. Epub 2010 Apr 8.
- Ho PA, Zeng R, Alonzo TA, Gerbing RB, Miller KL, Pollard JA, Stirewalt DL, Heerema NA, Raimondi SC, Hirsch B, Franklin JL, Lange B, Meshinchi S. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood. 2010 Aug 5;116(5):702-10. doi: 10.1182/blood-2010-02-268953. Epub 2010 Apr 22.
- Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 Aug;55(2):248-53. doi: 10.1002/pbc.22519.
- Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, Dahl G, Lacayo NJ, Becton D, Chang M, Weinstein HJ, Hirsch B, Raimondi SC, Heerema NA, Woods WG, Lange BJ, Hurwitz C, Arceci RJ, Radich JP, Bernstein ID, Heinrich MC, Meshinchi S. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010 Mar 25;115(12):2372-9. doi: 10.1182/blood-2009-09-241075. Epub 2010 Jan 7.
- Berman JN, Gerbing RB, Sung L, et al.: Prevalence and clinical implications of N-RAS mutations in childhood AML - A report from the Children's Oncology Group. [Abstract] Blood 114 (22): A-3115, 2009.
- Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B, Franklin JL, Radich JP, Meshinchi S. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood. 2009 Jun 25;113(26):6558-66. doi: 10.1182/blood-2008-10-184747. Epub 2009 Mar 20.
- Sung L, Alonzo TA, Gerbing RB, Aplenc R, Lange BJ, Woods WG, Feusner J, Franklin J, Patterson MJ, Gamis AS; Children's Oncology Group. Respiratory syncytial virus infections in children with acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2008 Dec;51(6):784-6. doi: 10.1002/pbc.21710.
- Pollard J, Alonzo T, Gerbing R, et al.: Prevalence and prognostic significance of c-KIT mutations in pediatric CBF AML patients enrolled on serial CCG/COG protocols. [Abstract] Blood 110 (11): A-1442, 2007.
- Cooper TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, Hirsch B, Smith FO, Mathew P, Arceci RJ, Feusner J, Iannone R, Lavey RS, Meshinchi S, Gamis A. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer. 2012 Feb 1;118(3):761-9. doi: 10.1002/cncr.26190. Epub 2011 Jul 15.
- Gudgeon CJ, Harrington KH, Laszlo GS, Alonzo TA, Gerbing RB, Gamis AS, Raimondi SC, Hirsch BA, Meshinchi S, Walter RB. High expression of neutrophil elastase predicts improved survival in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma. 2013 Jan;54(1):202-4. doi: 10.3109/10428194.2012.700480. Epub 2012 Jul 9. No abstract available.
- Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, Ho PA, Franklin J, Cooper TM, Gamis AS, Meshinchi S. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood. 2012 Aug 23;120(8):1581-8. doi: 10.1182/blood-2012-02-408336. Epub 2012 May 30.
- Ho PA, Kutny MA, Alonzo TA, Gerbing RB, Joaquin J, Raimondi SC, Gamis AS, Meshinchi S. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Aug;57(2):204-9. doi: 10.1002/pbc.23179. Epub 2011 Apr 18.
- Walter RB, Alonzo TA, Gerbing RB, Ho PA, Smith FO, Raimondi SC, Hirsch BA, Gamis AS, Franklin JL, Hurwitz CA, Loken MR, Meshinchi S. High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group. J Clin Oncol. 2010 Jun 10;28(17):2831-8. doi: 10.1200/JCO.2009.27.5693. Epub 2010 Apr 26.
- Walter RB, Alonzo TA, Gerbing RB, et al.: High expression of the very late antigen (VLA)-4 (CD49d) integrin predicts for reduced risk of relapse and better outcome in pediatric acute myeloid leukemia (AML): A report from the Children's Oncology Group. [Abstract] Blood 114 (22): A-1592, 2009.
- Franklin J, Alonzo T, Hurwitz CA, et al.: COG AAML03P1: efficacy and safety in a pilot study of intensive chemotherapy including gemtuzumab in children newly diagnosed with acute myeloid leukemia (AML). [Abstract] Blood 112 (11): A- 136, 2008.
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
- 組織型別の新生物
- 新生物
- 白血病
- 白血病、骨髄性
- 白血病、骨髄性、急性
- 薬の生理作用
- 薬理作用の分子機構
- 抗感染剤
- 末梢神経系エージェント
- 抗ウイルス剤
- 核酸合成阻害剤
- 酵素阻害剤
- 鎮痛剤
- 感覚系エージェント
- 抗リウマチ剤
- 代謝拮抗薬、抗腫瘍薬
- 代謝拮抗剤
- 抗悪性腫瘍薬
- 免疫抑制剤
- 免疫学的要因
- 抗悪性腫瘍薬、アルキル化
- アルキル化剤
- 骨髄破壊的アゴニスト
- 抗悪性腫瘍剤、ファイトジェニック
- トポイソメラーゼ II 阻害剤
- トポイソメラーゼ阻害剤
- 抗悪性腫瘍剤、免疫
- 皮膚科用薬
- 抗生物質、抗悪性腫瘍薬
- 抗真菌剤
- 生殖制御剤
- 妊娠中絶薬、非ステロイド系
- 中絶エージェント
- 葉酸拮抗薬
- カルシニューリン阻害剤
- シクロホスファミド
- エトポシド
- シタラビン
- メトトレキサート
- ダウノルビシン
- アスパラギナーゼ
- ミトキサントロン
- ブスルファン
- シクロスポリン
- シクロスポリン
- ゲムツズマブ
その他の研究ID番号
- AAML03P1
- CDR0000330133 (その他の識別子:Clinical Trials.gov)
- COG-AAML03P1 (その他の識別子:Children's Oncology Group)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。